Perseus Proteomics, Inc. (JP:4882) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perseus Proteomics, Inc. has announced promising results from the phase I clinical trial of its novel antibody PPMX-T003, targeting polycythemia vera, presented at the ASH Annual Meeting. The trial demonstrated safety and potential efficacy, as participants experienced a 12-week period without phlebotomy and no serious side effects. This development marks a significant step forward for the company’s innovative antibody therapies.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.